<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-037627</identifier>
<setSpec>0001-7310</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Langerhans cell histiocytosis</dc:title>
<dc:description xml:lang="en">Histiocytoses originate from the proliferation of mononuclear phagocytes in different tissues. These entities make up a heterogeneous group, and are mainly classified as Langerhans cell histiocytoses and non-Langerhans cell histiocytoses.         Langerhans cell histiocytoses have as a common characteristic the proliferation of dendritic antigen-presenting cells with phenotypical and ultrastructural characteristics of Langerhans cells.         Infiltration may be limited to one organ, or may be disseminated. The prognosis and the treatment especially depend on the age of the patient and the number and dysfunction of the organs involved. Its etiopathogenesis is unknown, although most researchers currently believe that an alteration in the regulation of the immunological system occurs in these patients</dc:description>
<dc:creator>Bueno, Celso</dc:creator>
<dc:creator>Valdivielso, Marta</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las histiocitosis se originan por la proliferación de células del sistema fagocítico mononuclear en diferentes tejidos. Estas entidades conforman un grupo heterogéneo, y principalmente se clasifican en histiocitosis de células de Langerhans e histiocitosis de células no Langerhans.         Las histiocitosis de células de Langerhans tienen en común la proliferación de células dendríticas presentadoras de antígeno con características fenotípicas y ultraestructurales de células de Langerhans. La infiltración puede limitarse a un órgano, o ser diseminada. El pronóstico y el tratamiento dependen sobre todo de la edad del paciente y del número y disfunción de los órganos afectados. La etiopatogenia es desconocida, aunque en la actualidad la mayor parte de los investigadores cree que se produce una alteración en la regulación del sistema inmunológico en estos pacientes</dc:description>
<dc:source>Actas Dermosifiliogr;96(5): 275-284, jun. 2005. ilus, tab</dc:source>
<dc:identifier>ibc-037627</dc:identifier>
<dc:title xml:lang="es">Histiocitosis de células de Langerhans</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29271^s22027</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8436^s22046</dc:subject>
<dc:subject>^d7291^s22053</dc:subject>
<dc:subject>^d28223^s22027</dc:subject>
<dc:subject>^d28001^s22016</dc:subject>
<dc:subject>^d28001^s22046</dc:subject>
<dc:subject>^d7291^s22046</dc:subject>
<dc:subject>^d29271^s22032</dc:subject>
<dc:subject>^d28223^s22032</dc:subject>
<dc:subject>^d12888^s22027</dc:subject>
<dc:subject>^d12888^s22032</dc:subject>
<dc:subject>^d28223^s22046</dc:subject>
<dc:subject>^d29271^s22046</dc:subject>
<dc:type>article</dc:type>
<dc:date>200506</dc:date>
</metadata>
</record>
</ibecs-document>
